Characteristics of study patients
| . | Total = 25, n (%), or median (range) . |
|---|---|
| Study groups | |
| Cohort I (dose escalation) | 15 (60) |
| Cohort II (MTD expansion) | 10 (40) |
| Pomalidomide dose level, mg/d | |
| 3 | 3 (12) |
| 5 | 16 (64) |
| 7 | 6 (24) |
| Age, y | |
| <60 | 7 (28) |
| ≥60 | 18 (72) |
| Sex | |
| Male | 13 (52) |
| Female | 12 (48) |
| Diagnosis | |
| PCNSL | 23 (92) |
| PVRL | 2 (8) |
| Relapsed vs refractory | |
| Relapsed | 20 (80) |
| Refractory | 5 (20) |
| Brain parenchymal involvement | 21 (84) |
| Eye involvement | 7 (28) |
| CSF involvement | 3 (12) |
| No. of prior treatments | 3 (1-11) |
| Time between previous treatment and study treatment, mo | |
| <6 | 13 (52) |
| 6-12 | 5 (20) |
| >12 | 7 (28) |
| Prior autologous stem cell transplant | 5 (20) |
| Prior high-dose methotrexate | 24 (96) |
| Prior rituximab | 22 (88) |
| Prior radiotherapy | 10 (40) |
| Best response to study treatment | |
| CR | 6 (24) |
| CRu | 2 (8) |
| PR | 4 (16) |
| SD | 7 (28) |
| Off-treatment reason, n = 19 | |
| Refused further treatment | 1 (5.3) |
| Adverse event | 1 (5.3) |
| Disease progression | 15 (79) |
| Died on study | 1 (5.3) |
| Other: cognitive decline | 1 (5.3) |
| Cause of death, n = 11 | |
| Aspiration pneumonia | 1 (9.1) |
| Due to PCNSL or PVRL | 10 (90.9) |
| . | Total = 25, n (%), or median (range) . |
|---|---|
| Study groups | |
| Cohort I (dose escalation) | 15 (60) |
| Cohort II (MTD expansion) | 10 (40) |
| Pomalidomide dose level, mg/d | |
| 3 | 3 (12) |
| 5 | 16 (64) |
| 7 | 6 (24) |
| Age, y | |
| <60 | 7 (28) |
| ≥60 | 18 (72) |
| Sex | |
| Male | 13 (52) |
| Female | 12 (48) |
| Diagnosis | |
| PCNSL | 23 (92) |
| PVRL | 2 (8) |
| Relapsed vs refractory | |
| Relapsed | 20 (80) |
| Refractory | 5 (20) |
| Brain parenchymal involvement | 21 (84) |
| Eye involvement | 7 (28) |
| CSF involvement | 3 (12) |
| No. of prior treatments | 3 (1-11) |
| Time between previous treatment and study treatment, mo | |
| <6 | 13 (52) |
| 6-12 | 5 (20) |
| >12 | 7 (28) |
| Prior autologous stem cell transplant | 5 (20) |
| Prior high-dose methotrexate | 24 (96) |
| Prior rituximab | 22 (88) |
| Prior radiotherapy | 10 (40) |
| Best response to study treatment | |
| CR | 6 (24) |
| CRu | 2 (8) |
| PR | 4 (16) |
| SD | 7 (28) |
| Off-treatment reason, n = 19 | |
| Refused further treatment | 1 (5.3) |
| Adverse event | 1 (5.3) |
| Disease progression | 15 (79) |
| Died on study | 1 (5.3) |
| Other: cognitive decline | 1 (5.3) |
| Cause of death, n = 11 | |
| Aspiration pneumonia | 1 (9.1) |
| Due to PCNSL or PVRL | 10 (90.9) |